Literature DB >> 17146090

Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario.

Muhammad Mamdani1, Leanne Warren, Alex Kopp, J Michael Paterson, Andreas Laupacis, Ken Bassett, Geoffrey M Anderson.   

Abstract

BACKGROUND: Population rates of upper gastrointestinal (GI) hemorrhage have been observed to increase with the introduction and rapid uptake of selective cyclooxygenase-2 (COX-2) inhibitors. Changes in COX-2 inhibitor use and upper GI bleeding rates in regions with relatively restrictive drug policies (e.g., British Columbia) have not been compared with changes in regions with relatively less restrictive drug policies (e.g., Ontario).
METHODS: We collected administrative data for about 1.4 million people aged 66 years and older in British Columbia and Ontario for the period January 1996 to November 2002. We examined temporal changes in the prevalence of NSAID use and admissions to hospital because of upper GI hemorrhage in both provinces using cross-sectional time series analysis.
RESULTS: During the period studied, the prevalence of NSAID use in British Columbia's population of older people increased by 25% (from 8.7% to 10.9%; p < 0.01), as compared with a 51% increase in Ontario (from 10.9% to 16.5%; p < 0.01). Hospital admissions because of upper GI hemorrhage increased significantly in Ontario by about 16% on average, or about 2 admissions per 10 000 elderly people, above expected values (p < 0.01). A similar increase was not observed in British Columbia.
INTERPRETATION: More restrictive drug coverage policies, although limiting access to drugs and their potential benefits, may protect the population from adverse drug effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146090      PMCID: PMC1660595          DOI: 10.1503/cmaj.050192

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  6 in total

1.  Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.

Authors:  Muhammad Mamdani; Paula Rochon; Andreas Laupacis; Geoffrey Anderson
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

2.  Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study.

Authors:  Muhammad Mamdani; David N Juurlink; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal:  BMJ       Date:  2004-05-11

3.  Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database.

Authors:  D S Raiford; S Pérez Gutthann; L A García Rodríguez
Journal:  Epidemiology       Date:  1996-01       Impact factor: 4.822

4.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

5.  Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors:  Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal:  BMJ       Date:  2002-09-21

6.  Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland.

Authors:  Briegeen Girvin; Thérèse Rafferty; Michael R Stevenson; G Dennis Johnston
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-03       Impact factor: 2.890

  6 in total
  6 in total

1.  A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

Authors:  John-Michael Gamble; Dean T Eurich; Jeffrey A Johnson
Journal:  Healthc Policy       Date:  2010-11

Review 2.  Observational studies and their utility for practice.

Authors:  Julia Fm Gilmartin-Thomas; Danny Liew; Ingrid Hopper
Journal:  Aust Prescr       Date:  2018-06-01

Review 3.  Pharmaceutical policies: effects of restrictions on reimbursement.

Authors:  Carolyn J Green; Malcolm Maclure; Patricia M Fortin; Craig R Ramsay; Morten Aaserud; Stan Bardal
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

4.  The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.

Authors:  Bogdan Superceanu; Sander Veldhuyzen van Zanten; Chris Skedgel; Michael Shepherd; Ingrid Sketris
Journal:  Can J Gastroenterol       Date:  2010-08       Impact factor: 3.522

5.  Impact of drug policy on regional trends in ezetimibe use.

Authors:  Lingyun Lu; Harlan M Krumholz; Jack V Tu; Joseph S Ross; Dennis T Ko; Cynthia A Jackevicius
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-06-03

6.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.